<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04117152</url>
  </required_header>
  <id_info>
    <org_study_id>ParisTRCOT_CAV</org_study_id>
    <nct_id>NCT04117152</nct_id>
  </id_info>
  <brief_title>Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation</brief_title>
  <acronym>TRAJ-CAV</acronym>
  <official_title>Multicenter International Observational Study to Identify Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation and Their Specific Determinants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paris Translational Research Center for Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupe Hospitalier Pitie-Salpetriere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Paris Translational Research Center for Organ Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims: i) to identify Cardiac Allograft Vasculopathy (CAV) trajectories after
      heat transplantation using latent class mixed modeling, ii) to characterize the global and
      specific determinants of different trajectories and iii) to provide an easily accessible tool
      to project individual probability of CAV trajectory belonging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Cardiac Allograft Vasculopathy (CAV) is the third cause of late mortality and the leading
      cause of late allograft dysfunction. The field of heart transplantation currently lacks
      longitudinal description of CAV profiles. Identifying relevant CAV trajectories, or evolution
      profiles, and their respective determinants is an unmet clinical need. CAV trajectories
      requires an additional level of understanding and characterization over the current paradigm.
      Understanding the mechanisms and clinical factors involved in the development of CAV will be
      useful to provide a more nuanced picture of disease progression, which may ultimately
      contribute to risk stratification and ultimately guiding the care of HTx patients.

      Main Outcome(s) and Measure(s):

        -  Identification of CAV trajectories after transplantation using an unsupervised latent
           class mixed modeling. CAV angiograms were recorded per center protocol for all patients
           after transplantation. CAV was graded according to the current ISHLT classification as
           CAV 0 (not significant), 1 (mild), 2 (moderate) and 3 (severe).

        -  Determination of clinical, functional, structural, immunological factors associated with
           the trajectories. In the derivation cohort, the associations between CAV trajectories
           and clinical, histological, functional, and immunological parameters at the time of
           transplantation, during the first year and at one-year post-transplant were assessed
           using multinomial logistic regression.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2004</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Identification of trajectories of Cardiac Allograft Vasculopathy (CAV)</measure>
    <time_frame>10 years post-transplant</time_frame>
    <description>Identification of different evolutive profiles of CAV using latent classes mixed models. Each coronary angiogram was graded from 0 (no CAV) to 3 (severe CAV) according to ISHLT classification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of the specific determinants of CAV trajectories</measure>
    <time_frame>From transplantation to 1-year post-transplant</time_frame>
    <description>Identification of immune and non-immune determinants using multivariable multinomial logistic regression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early prediction of CAV trajectories</measure>
    <time_frame>10 years post-transplant</time_frame>
    <description>Probability of belonging to each trajectory according to the baseline angiogram and independent risk factors for CAV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients and allograft survival probability according the CAV trajectory</measure>
    <time_frame>10 years post-transplant</time_frame>
    <description>Comparison of prognosis according the CAV trajectory</description>
  </secondary_outcome>
  <enrollment type="Actual">1300</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Allograft Arteriopathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Latent class mixed modeling</intervention_name>
    <description>To identify CAV trajectories after heart transplantation using a contemporary unsupervised trajectory-based approach known as latent class mixed modeling</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Heart recipients aged over 18 and of all genders recruited between 2004 and 2015 from
        European and North American centers, who had at least two coronary angiograms during
        follow-up.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart recipient with at least two coronary angiograms after heart transplantation,

          -  Heart recipient over 18 years of age.

        Exclusion Criteria:

          -  Patient with &lt; 2 coronary angiograms during follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Loupy, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Transplant Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jon Kobashigawa</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maarten Naesens</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris Transplant Group</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2019</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

